Gaudium IVF and Women Health Limited announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The Board also approved a variation in the objects of its Initial Public Offer (IPO), specifically regarding the establishment of 19 new IVF centres. This includes changing six cities/locations and revising the establishment schedule, with all centres targeted by Fiscal 2029, subject to shareholder approval.
Board Meeting Outcome
Gaudium IVF and Women Health Limited has reported the outcome of its Board Meeting held on November 12, 2026. Key decisions included the approval of the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. These results, along with the limited review report from M/s. SKGN & Associates LLP, have been shared.
IPO Fund Utilization Variation
A significant resolution passed was the approval of a variation in the objects of the Initial Public Offer (IPO). This variation pertains to Object No. 1 – the establishment of 19 New IVF Centres. The changes involve the change or substitution of 6 cities/locations and a revision of the establishment schedule, with all 19 centres expected to be operational by Fiscal 2029. This proposed variation is subject to shareholder approval via a Special Resolution through Postal Ballot.
Senior Management Appointment
In addition, the Board approved the appointment of Dr. Ravish Manchanda as National Head – Operations Expansion & Strategy, effective November 12, 2026. He has been designated as a Senior Management Personnel (SMP) of the Company.
Policy Amendment
The Board also approved an amendment to the Company’s Policy on Code of practices and procedures for fair disclosure of unpublished price sensitive information, aligning it with SEBI (Prohibition of Insider Trading) Regulations, 2015. The amended policy will be available on the company website.
Financial Highlights
The unaudited standalone financial results show a profit for the quarter ended September 30, 2026, of ₹819.97 lakhs. For the half-year ended September 30, 2026, the profit stands at ₹986.31 lakhs. The consolidated results for the quarter ended September 30, 2026, reported a profit of ₹937.91 lakhs, and for the half-year ended September 30, 2026, the profit was ₹1,118.91 lakhs.
Source: BSE
